Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $53.00 Average Price Target from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $53.00.

COLL has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target (up from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday, January 9th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Weiss Ratings reissued a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 29th. Finally, Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a research report on Tuesday, February 10th.

Collegium Pharmaceutical Stock Performance

COLL opened at $39.61 on Monday. The firm’s fifty day simple moving average is $45.98 and its two-hundred day simple moving average is $42.12. Collegium Pharmaceutical has a 52-week low of $23.23 and a 52-week high of $50.79. The company has a market cap of $1.26 billion, a price-to-earnings ratio of 23.16 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.57 and a debt-to-equity ratio of 2.59.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The company had revenue of $205.45 million for the quarter, compared to analyst estimates of $206.36 million. During the same quarter last year, the company earned $1.77 EPS. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. Equities analysts anticipate that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Rita J. Balice-Gordon sold 3,650 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the sale, the director directly owned 52,629 shares in the company, valued at approximately $2,475,141.87. This trade represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00. Following the completion of the transaction, the executive vice president owned 103,613 shares in the company, valued at $4,991,038.21. The trade was a 14.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.51% of the stock is owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Illinois Municipal Retirement Fund lifted its holdings in Collegium Pharmaceutical by 1.6% in the third quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock valued at $605,000 after acquiring an additional 278 shares during the last quarter. Vident Advisory LLC raised its position in Collegium Pharmaceutical by 1.9% in the third quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock valued at $541,000 after purchasing an additional 281 shares during the period. Quadrant Capital Group LLC raised its position in Collegium Pharmaceutical by 4.2% in the fourth quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock valued at $324,000 after purchasing an additional 282 shares during the period. GAMMA Investing LLC lifted its stake in shares of Collegium Pharmaceutical by 9.6% in the 4th quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 285 shares during the last quarter. Finally, Atom Investors LP grew its holdings in shares of Collegium Pharmaceutical by 5.0% during the 4th quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock worth $284,000 after purchasing an additional 294 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.